Extendicare Valuation
| EXE Stock | CAD 10.38 0.04 0.39% |
At this time, the firm appears to be undervalued. Extendicare shows a prevailing Real Value of C$11.71 per share. The current price of the firm is C$10.38. Our model computes the value of Extendicare from reviewing the firm fundamentals such as Current Valuation of 1.03 B, shares outstanding of 83.47 M, and Profit Margin of 0.04 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Extendicare's valuation include:
Price Book 7.6211 | Enterprise Value 1 B | Enterprise Value Ebitda 7.3878 | Price Sales 0.6241 | Forward PE 17.0068 |
Undervalued
Today
Please note that Extendicare's price fluctuation is not too volatile at this time. Calculation of the real value of Extendicare is based on 3 months time horizon. Increasing Extendicare's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Extendicare is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Extendicare Stock. However, Extendicare's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.38 | Real 11.71 | Hype 10.37 | Naive 10.61 |
The intrinsic value of Extendicare's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Extendicare's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Extendicare helps investors to forecast how Extendicare stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Extendicare more accurately as focusing exclusively on Extendicare's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Extendicare's intrinsic value based on its ongoing forecasts of Extendicare's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Extendicare's closest peers.
Extendicare Cash |
|
Extendicare Valuation Trend
Knowing Extendicare's actual value is paramount for traders when making sound investment determinations. Using both Extendicare's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Extendicare Total Value Analysis
Extendicare is currently forecasted to have takeover price of 1.03 B with market capitalization of 866.39 M, debt of 334.52 M, and cash on hands of 167.28 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Extendicare fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.03 B | 866.39 M | 334.52 M | 167.28 M |
Extendicare Investor Information
About 14.0% of the company shares are held by company insiders. The company last dividend was issued on the 31st of October 2024. Extendicare had 43:40 split on the 10th of November 2006. Based on the measurements of operating efficiency obtained from Extendicare's historical financial statements, Extendicare may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.077 | 0.0857 |
|
| |||||
| Operating Income | 92.7 M | 62.6 M |
|
|
Extendicare Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Extendicare has an asset utilization ratio of 193.98 percent. This suggests that the Company is making C$1.94 for each dollar of assets. An increasing asset utilization means that Extendicare is more efficient with each dollar of assets it utilizes for everyday operations.Extendicare Ownership Allocation
Extendicare holds a total of 83.47 Million outstanding shares. Extendicare shows 13.92 percent of its outstanding shares held by insiders and 19.14 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Extendicare Profitability Analysis
The company reported the revenue of 1.3 B. Net Income was 33.98 M with profit before overhead, payroll, taxes, and interest of 108.53 M.Extendicare Past Distributions to stockholders
About Extendicare Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Extendicare. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Extendicare based exclusively on its fundamental and basic technical indicators. By analyzing Extendicare's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Extendicare's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Extendicare. We calculate exposure to Extendicare's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Extendicare's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 118.4 M | 112.5 M | |
| Pretax Profit Margin | 0.03 | 0.04 | |
| Operating Profit Margin | 0.09 | 0.08 | |
| Net Profit Margin | 0.03 | 0.02 | |
| Gross Profit Margin | 0.09 | 0.13 |
Other Information on Investing in Extendicare Stock
Extendicare financial ratios help investors to determine whether Extendicare Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Extendicare with respect to the benefits of owning Extendicare security.